These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64 related articles for article (PubMed ID: 5109498)
1. [Highly dispersive -Al 2 O 3 -aerosol as an adjuvant in preparation of inactivated viral or mixed vaccines]. Grafe A Arzneimittelforschung; 1971 Jul; 21(7):903-5. PubMed ID: 5109498 [No Abstract] [Full Text] [Related]
2. Potentiation of the immune response to non-adsorbed antigens by aluminum-containing adjuvants. Romero Méndez IZ; Shi Y; HogenEsch H; Hem SL Vaccine; 2007 Jan; 25(5):825-33. PubMed ID: 17014935 [TBL] [Abstract][Full Text] [Related]
3. Characterization of aluminium-containing adjuvants. White JL; Hem SL Dev Biol (Basel); 2000; 103():217-28. PubMed ID: 11214239 [TBL] [Abstract][Full Text] [Related]
4. Immunogenicity in mice of anthrax recombinant protective antigen in the presence of aluminum adjuvants. Berthold I; Pombo ML; Wagner L; Arciniega JL Vaccine; 2005 Mar; 23(16):1993-9. PubMed ID: 15734073 [TBL] [Abstract][Full Text] [Related]
5. Experimental squalene adjuvant. I. Preparation and testing of its effectiveness. Süli J; Benísek Z; Eliás D; Svrcek S; Ondrejková A; Ondrejka R; Bajová V Vaccine; 2004 Sep; 22(25-26):3464-9. PubMed ID: 15308373 [TBL] [Abstract][Full Text] [Related]
6. Relationship between the strength of antigen adsorption to an aluminum-containing adjuvant and the immune response. Hansen B; Sokolovska A; HogenEsch H; Hem SL Vaccine; 2007 Sep; 25(36):6618-24. PubMed ID: 17681647 [TBL] [Abstract][Full Text] [Related]
7. Characterization of aluminum hydroxide for use as an adjuvant in parenteral vaccines. Hem SL; White JL J Parenter Sci Technol; 1984; 38(1):2-10. PubMed ID: 6423795 [No Abstract] [Full Text] [Related]
8. Comparison of the effects of five adjuvants on the antibody response to influenza virus antigen in guinea pigs. Robuccio JA; Griffith JW; Chroscinski EA; Cross PJ; Light TE; Lang CM Lab Anim Sci; 1995 Aug; 45(4):420-6. PubMed ID: 7474883 [TBL] [Abstract][Full Text] [Related]
9. Adsorption of cobalt species on the interface, which is developed between aqueous solution and metal oxides used for the preparation of supported catalysts: a critical review. Bourikas K; Kordulis C; Vakros J; Lycourghiotis A Adv Colloid Interface Sci; 2004 Aug; 110(3):97-120. PubMed ID: 15328060 [TBL] [Abstract][Full Text] [Related]
11. Effect of the strength of adsorption of hepatitis B surface antigen to aluminum hydroxide adjuvant on the immune response. Hansen B; Belfast M; Soung G; Song L; Egan PM; Capen R; Hogenesch H; Mancinelli R; Hem SL Vaccine; 2009 Feb; 27(6):888-92. PubMed ID: 19071182 [TBL] [Abstract][Full Text] [Related]
12. Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. Hem SL; Hogenesch H Expert Rev Vaccines; 2007 Oct; 6(5):685-98. PubMed ID: 17931150 [TBL] [Abstract][Full Text] [Related]
13. Distribution of adsorbed antigen in mono-valent and combination vaccines. Morefield GL; HogenEsch H; Robinson JP; Hem SL Vaccine; 2004 May; 22(15-16):1973-84. PubMed ID: 15121310 [TBL] [Abstract][Full Text] [Related]
14. Effect of phosphorylation of ovalbumin on adsorption by aluminum-containing adjuvants and elution upon exposure to interstitial fluid. Morefield GL; Jiang D; Romero-Mendez IZ; Geahlen RL; Hogenesch H; Hem SL Vaccine; 2005 Feb; 23(12):1502-6. PubMed ID: 15670886 [TBL] [Abstract][Full Text] [Related]
15. [Studies on the suitability of basic aluminum chloride as adjuvant in the production of erysipelas adsorbate vaccine]. Meese M; Gürtler D Arch Exp Veterinarmed; 1966 Mar; 20(1):141-50. PubMed ID: 5983260 [No Abstract] [Full Text] [Related]
16. [Possibilities of preserving aluminum phosphate gel]. Gafiţanu E; Voitcu M; Matei I; Grosu G Rev Med Chir Soc Med Nat Iasi; 1987; 91(3):537-40. PubMed ID: 3445055 [No Abstract] [Full Text] [Related]
17. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model. Ninomiya A; Imai M; Tashiro M; Odagiri T Vaccine; 2007 May; 25(18):3554-60. PubMed ID: 17293015 [TBL] [Abstract][Full Text] [Related]